Skip to content

Clinical study on the treatment of uric acid nephropathy by high colon route of Yiqing Recipe

Clinical study on the treatment of uric acid nephropathy by high colon route of Yiqing Recipe

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049525
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-07-28
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uric acid nephropathy

Interventions

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnostic criteria: meet the diagnostic criteria for uric acid nephropathy; 2. Patients with chronic kidney disease (CKD) stage 1-4; 3. Aged 16 to 78 years; 4. Patients who accept this study and agree to sign the informed consent form, who can cooperate on time; 5. TCM syndrome classification and quantification basis: refer to the "Guidelines for Clinical Research on New Chinese Medicines" and "Uric Acid Nephropathy Diagnosis, Syndrome Differentiation and Efficacy Judgment" designated by the Nephrology Branch of the Chinese Traditional Chinese Medicine Association in 2008, which belong to the spleen and kidney. Patients with qi deficiency, liver and kidney yin deficiency, qi and yin deficiency, concurrent wet turbidity, and blood stasis syndrom; 6. Those who did not use traditional Chinese medicine or western medicine to lower uric acid in the 2 weeks before the test, or those who used related drugs but stopped for more than 2 weeks to wash out; 7. For long-term use of hydrochlorothiazide and other drugs that affect blood uric acid, and can replace other drugs, a 2-week washout period after stopping and changing the drug.

Exclusion criteria

Exclusion criteria: 1. Renal damage or secondary hyperuricemia caused by other reasons; 2. Taking other drugs that affect renal function; 3. Patients with acute severe infection lesions; 4. Patients with severe colorectal diseases such as hemorrhoids and anal fistula; 5. Patients with serious primary diseases such as heart, kidney, liver, brain, and hematopoietic system, and are in the acute exacerbation stage; 6. Pregnant or lactating women; 7. Those who are allergic to allopurinol or have a positive HLA-B 5801 gene test.

Design outcomes

Primary

MeasureTime frame
Red blood cell count;platelet count;Neutrophil ratio;Lymphocyte ratio;Urine protein;Urine red blood cells;24h urine protein quantification;Urine NAG enzyme;Urine osmotic pressure;Serum creatinine;urea nitrogen;blood uric acid;Cystatin C;Homocysteine;alanine aminotransferase;albumin;C reactive protein;Prothrombin time;Tumor necrosis factor-a;Interferon-?;interleukin-2;interleukin-4;interleukin-6;interleukin-10;Left kidney glomerular filtration rate;Right kidney glomerular filtration rate;Total glomerular filtration rate;

Secondary

MeasureTime frame
hemoglobin;White blood cell count;Urine Leukocytes;Urine Specific Gravity;Urine PH;Total bilirubin;Direct bilirubin;Indirect bilirubin;

Countries

China

Contacts

Public ContactZhou Jin

Shenzhen Second People's Hospital

2993754876@qq.com+86 13823766092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026